Opendata, web and dolomites

FutureTrophicFactors SIGNED

Elucidating therapeutic effects and mode of action of future trophic factorsin ALS and Parkinson’s disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FutureTrophicFactors project word cloud

Explore the words cloud of the FutureTrophicFactors project. It provides you a very rough idea of what is the project "FutureTrophicFactors" about.

action    pluripotent    neurons    explored    sclerosis    parkinson    relieve    branching    ntfs    data    trophic    pd    vivo    nerve    variant    prevalence    function    enters    restores    ips    despite    innovative    treatments    direct    urgent    neurorestorative    cell    effect    understand    peptides    stop    fragment    protein    measured    difficulty    culture    stem    therapies    subcutaneously    invasive    showed    efficacy    neurotrophic    discovery    progression    groundbreaking    cultures    ultimate    proteins    rhesus    treatment    animal    survival    protects    symptoms    surgery    treat    human    lateral    diseases    models    toxin    aging    monkey    patients    neurite    regulate    population    dopamine    model    secretary    cells    overcome    trials    cdnf    administered    disease    peripheral    neurodegenerative    poor    da    therapeutic    clinical    motor    amyotrophic    life    pass    bbb    drawbacks    vitro    brain    rodent    ohda    blood    penetrating    mode    als    polypeptides    drugs    expectancy    ntf    barrier    treating   

Project "FutureTrophicFactors" data sheet

The following table provides information about the project.

Coordinator
HELSINGIN YLIOPISTO 

Organization address
address: YLIOPISTONKATU 3
city: HELSINGIN YLIOPISTO
postcode: 14
website: www.helsinki.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 1˙497˙597 €
 EC max contribution 1˙497˙597 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-STG
 Funding Scheme ERC-STG
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2024-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) coordinator 1˙497˙597.00

Map

 Project objective

The prevalence of neurodegenerative diseases such as Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) is growing rapidly due to an aging population and increased life expectancy. Current treatments for ALS and PD only relieve symptoms and cannot stop the progression of the disease, thus there is an urgent need for new therapies. Neurotrophic factors (NTFs) are secretary proteins that regulate the survival of neurons, neurite growth and branching. They have been explored as novel drugs for the treatment of ALS and PD but their efficacy in clinical trials is poor. CDNF is a protein with NTF properties that protects and restores the function of dopamine neurons in rodent and rhesus monkey toxin models of PD more effectively than other NTFs. CDNF is currently in phase 1/2 clinical trials on PD patients. Despite promising results with CDNF in animal models of PD, NTF and CDNF-based treatments have drawbacks. CDNF requires direct delivery to the brain through invasive surgery since, it cannot pass through the blood brain barrier (BBB). My recent discovery, however, may overcome this difficulty: I showed that a novel CDNF variant protects DA neurons in vitro and in vivo and that it efficiently enters DA neurons in culture. Furthermore, my data show the CDNF fragment can pass through the BBB as measured by 3 different methods and has a neurorestorative effect in a 6-OHDA toxin model of PD when administered subcutaneously. The ultimate goal of my research is to understand the mode of action and therapeutic effect of novel BBB penetrating CDNF-derived polypeptides in cultures of human induced pluripotent stem (iPS) cell-derived nerve cells from patients and in animal models of ALS and PD. The innovative aspect of this proposal is the new groundbreaking concept for treating neurodegenerative diseases – peripheral delivery of BBB penetrating peptides with trophic factor properties and the potential to treat non-motor and motor symptoms in ALS and PD patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FUTURETROPHICFACTORS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FUTURETROPHICFACTORS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DimorphicCircuits (2019)

Elucidating the development of sexually-dimorphic circuits: from molecular mechanisms to synapses and behavior

Read More